Sera Prognostics Announces Proposed Public Offering

Core Viewpoint - Sera Prognostics, Inc. has announced a proposed underwritten public offering of its Class A common stock to enhance its commercial infrastructure and capabilities, particularly in the U.S. and for potential expansion into the European Union [1][3]. Group 1: Offering Details - The company is offering Class A common stock and pre-funded warrants to purchase shares of Class A common stock, with underwriters granted a 30-day option to purchase up to an additional 15% of the total shares offered [1]. - Jefferies, TD Cowen, and William Blair are acting as joint book-running managers, while RBC Capital Markets is serving as a bookrunner for the offering [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized to expand commercial infrastructure in the U.S., accelerate preparations for EU expansion, fund studies to increase adoption of the PreTRM test, and for general corporate purposes [3]. Group 3: Company Overview - Sera Prognostics is focused on improving maternal and neonatal health through innovative pregnancy biomarker information, with a mission to provide early pregnancy information to reduce healthcare delivery costs [6]. - The company has developed the PreTRM® Test, which assesses the risk of spontaneous premature delivery, allowing for proactive interventions [6].